162 related articles for article (PubMed ID: 21958427)
1. Genomic and phenotypic analysis of BRCA2 mutated breast cancers reveals co-occurring changes linked to progression.
Stefansson OA; Jonasson JG; Olafsdottir K; Bjarnason H; Th Johannsson O; Bodvarsdottir SK; Valgeirsdottir S; Eyfjord JE
Breast Cancer Res; 2011 Sep; 13(5):R95. PubMed ID: 21958427
[TBL] [Abstract][Full Text] [Related]
2. Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers.
Holstege H; van Beers E; Velds A; Liu X; Joosse SA; Klarenbeek S; Schut E; Kerkhoven R; Klijn CN; Wessels LF; Nederlof PM; Jonkers J
BMC Cancer; 2010 Aug; 10():455. PubMed ID: 20735817
[TBL] [Abstract][Full Text] [Related]
3. Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.
Stefansson OA; Jonasson JG; Johannsson OT; Olafsdottir K; Steinarsdottir M; Valgeirsdottir S; Eyfjord JE
Breast Cancer Res; 2009; 11(4):R47. PubMed ID: 19589159
[TBL] [Abstract][Full Text] [Related]
4. Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics.
Jönsson G; Staaf J; Vallon-Christersson J; Ringnér M; Holm K; Hegardt C; Gunnarsson H; Fagerholm R; Strand C; Agnarsson BA; Kilpivaara O; Luts L; Heikkilä P; Aittomäki K; Blomqvist C; Loman N; Malmström P; Olsson H; Johannsson OT; Arason A; Nevanlinna H; Barkardottir RB; Borg A
Breast Cancer Res; 2010; 12(3):R42. PubMed ID: 20576095
[TBL] [Abstract][Full Text] [Related]
5. Loss of heterozygosity at 13q13 and 14q32 predicts BRCA2 inactivation in luminal breast carcinomas.
Pécuchet N; Popova T; Manié E; Lucchesi C; Battistella A; Vincent-Salomon A; Caux-Moncoutier V; Bollet M; Sigal-Zafrani B; Sastre-Garau X; Stoppa-Lyonnet D; Stern MH
Int J Cancer; 2013 Dec; 133(12):2834-42. PubMed ID: 23754601
[TBL] [Abstract][Full Text] [Related]
6. Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization.
Jönsson G; Naylor TL; Vallon-Christersson J; Staaf J; Huang J; Ward MR; Greshock JD; Luts L; Olsson H; Rahman N; Stratton M; Ringnér M; Borg A; Weber BL
Cancer Res; 2005 Sep; 65(17):7612-21. PubMed ID: 16140926
[TBL] [Abstract][Full Text] [Related]
7. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
Joosse SA; Brandwijk KI; Devilee P; Wesseling J; Hogervorst FB; Verhoef S; Nederlof PM
Breast Cancer Res Treat; 2012 Apr; 132(2):379-89. PubMed ID: 20614180
[TBL] [Abstract][Full Text] [Related]
8. Deletion of chromosomes 13q and 14q is a common feature of tumors with BRCA2 mutations.
Rouault A; Banneau G; Macgrogan G; Jones N; Elarouci N; Barouk-Simonet E; Venat L; Coupier I; Letouzé E; de Reyniès A; Bonnet F; Iggo R; Sévenet N; Longy M
PLoS One; 2012; 7(12):e52079. PubMed ID: 23284877
[TBL] [Abstract][Full Text] [Related]
9. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations.
Tirkkonen M; Johannsson O; Agnarsson BA; Olsson H; Ingvarsson S; Karhu R; Tanner M; Isola J; Barkardottir RB; Borg A; Kallioniemi OP
Cancer Res; 1997 Apr; 57(7):1222-7. PubMed ID: 9102202
[TBL] [Abstract][Full Text] [Related]
10. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays.
Bane AL; Beck JC; Bleiweiss I; Buys SS; Catalano E; Daly MB; Giles G; Godwin AK; Hibshoosh H; Hopper JL; John EM; Layfield L; Longacre T; Miron A; Senie R; Southey MC; West DW; Whittemore AS; Wu H; Andrulis IL; O'Malley FP
Am J Surg Pathol; 2007 Jan; 31(1):121-8. PubMed ID: 17197928
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Sánchez L; Rivas C; Benítez J
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3606-14. PubMed ID: 14506147
[TBL] [Abstract][Full Text] [Related]
12. Multiple copies of mutant BRCA1 and BRCA2 alleles in breast tumors from germ-line mutation carriers.
Staff S; Nupponen NN; Borg A; Isola JJ; Tanner MM
Genes Chromosomes Cancer; 2000 Aug; 28(4):432-42. PubMed ID: 10862052
[TBL] [Abstract][Full Text] [Related]
13. The retinoblastoma gene undergoes rearrangements in BRCA1-deficient basal-like breast cancer.
Jönsson G; Staaf J; Vallon-Christersson J; Ringnér M; Gruvberger-Saal SK; Saal LH; Holm K; Hegardt C; Arason A; Fagerholm R; Persson C; Grabau D; Johnsson E; Lövgren K; Magnusson L; Heikkilä P; Agnarsson BA; Johannsson OT; Malmström P; Fernö M; Olsson H; Loman N; Nevanlinna H; Barkardottir RB; Borg Å
Cancer Res; 2012 Aug; 72(16):4028-36. PubMed ID: 22706203
[TBL] [Abstract][Full Text] [Related]
14. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.
Bertucci F; Rypens C; Finetti P; Guille A; Adélaïde J; Monneur A; Carbuccia N; Garnier S; Dirix P; Gonçalves A; Vermeulen P; Debeb BG; Wang X; Dirix L; Ueno NT; Viens P; Cristofanilli M; Chaffanet M; Birnbaum D; Van Laere S
Mol Oncol; 2020 Mar; 14(3):504-519. PubMed ID: 31854063
[TBL] [Abstract][Full Text] [Related]
15. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage.
Marcus JN; Watson P; Page DL; Narod SA; Lenoir GM; Tonin P; Linder-Stephenson L; Salerno G; Conway TA; Lynch HT
Cancer; 1996 Feb; 77(4):697-709. PubMed ID: 8616762
[TBL] [Abstract][Full Text] [Related]
16. Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer.
Staaf J; Jönsson G; Ringnér M; Baldetorp B; Borg A
Breast Cancer Res; 2011; 13(6):R129. PubMed ID: 22169037
[TBL] [Abstract][Full Text] [Related]
17. A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation.
Alvarez S; Diaz-Uriarte R; Osorio A; Barroso A; Melchor L; Paz MF; Honrado E; Rodríguez R; Urioste M; Valle L; Díez O; Cigudosa JC; Dopazo J; Esteller M; Benitez J
Clin Cancer Res; 2005 Feb; 11(3):1146-53. PubMed ID: 15709182
[TBL] [Abstract][Full Text] [Related]
18. EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry.
Bane AL; Mulligan AM; Pinnaduwage D; O'Malley FP; Andrulis IL
Breast Cancer Res Treat; 2011 Jun; 127(3):831-9. PubMed ID: 21327470
[TBL] [Abstract][Full Text] [Related]
19. Copy number profiling by array comparative genomic hybridization identifies frequently occurring BRCA2-like male breast cancer.
Biesma HD; Schouten PC; Lacle MM; Sanders J; Brugman W; Kerkhoven R; Mandjes I; van der Groep P; van Diest PJ; Linn SC
Genes Chromosomes Cancer; 2015 Dec; 54(12):734-44. PubMed ID: 26355282
[TBL] [Abstract][Full Text] [Related]
20. Genomic deletions in the BRCA1, BRCA2 and TP53 regions associate with low expression of the estrogen receptor in sporadic breast carcinoma.
Schmutzler RK; Bierhoff E; Werkhausen T; Fimmers R; Speiser P; Kubista E; Krebs D; Zeillinger R; Wiestler OD; Von Deimling A
Int J Cancer; 1997 Jun; 74(3):322-5. PubMed ID: 9221812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
